Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Phase 1 single-center, double-blind, randomized, placebo-controlled trial evaluating the safety, tolerability, and pharmacokinetics of HRX-0215 assessing a single and multiple dose escalation study (SAD/MAD)

Next Previous
Search
Trial Profile

The Phase 1 single-center, double-blind, randomized, placebo-controlled trial evaluating the safety, tolerability, and pharmacokinetics of HRX-0215 assessing a single and multiple dose escalation study (SAD/MAD)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HRX 215 (Primary)
  • Indications Liver disorders
  • Focus Adverse reactions; First in man
  • Sponsors HepaRegeniX

    • Most Recent Events

    • 20 Mar 2024 New trial record
    • 14 Mar 2024 Results presented in the HepaRegeniX Media Release.
    • 14 Mar 2024 According to HepaRegeniX media release, safety and tolerability data from this trial published in the journal Cell.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top